venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
Published 5 months ago • 348 plays • Length 5:34Download video MP4
Download video MP3
Similar videos
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
2:50
venetoclax and ibrutinib based approaches in cll
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
5:45
treatment effectiveness of venetoclax-based therapy after btki exposure in cll/sll
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
2:25
venetoclax for aml
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
1:39
retreatment with a btki plus venetoclax after relapse is effective in cll: insights from captivate
-
4:21
hovon 141/vision trial update: mrd-guided venetoclax ibrutinib treatment for r/r cll
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
2:04
time-limited venetoclax-rituximab in r/r cll patients previously exposed to btki’s
-
1:48
maic of pirtobrutinib vs venetoclax in patients with r/r cll previously treated with a covalent btki
-
2:08
the role of venetoclax in the treatment of cll
-
2:18
first-line ibrutinib and venetoclax in cll
-
2:05
results from the phase i sal-relax trial: venetoclax plus cytarabine and mitoxantrone in r/r aml
-
1:54
glow: assessing ibrutinib plus venetoclax in cll
-
1:03
maic of zanubrutinib and venetoclax ibrutinib in treatment-naïve cll
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation